Weisen and HangukPharma Join Forces to Sell AI Endoscopy Solution 'Weimed Endo'

Waycen and Korea Pharma announced on the 22nd that they have signed a strategic sales agreement for the AI-based stomach and colon endoscopy video analysis solution, 'WAYMED Endo.'

Eunhee Park, CEO of Korea Pharma (left), and Kyungnam Kim, CEO of Weisen, are posing for a commemorative photo at the signing ceremony of the strategic sales contract and marketing partnership for AI-based upper and lower gastrointestinal endoscopy software.
[Photo by Korea Pharma]

This business agreement was made through mutual consultation between the two companies to strengthen competitiveness in the field of gastrointestinal endoscopy. Korea Pharma, which secured the domestic exclusive rights for 'Plenvu' from Norgine, a global bowel cleansing agent developer based in the Netherlands, and introduced it domestically since 2019, and Waycen, a leader in the AI gastrointestinal endoscopy software market, are expected to open a new chapter in the gastrointestinal endoscopy market.

WAYMED Endo is the first AI stomach and colon endoscopy software to receive approval from the Ministry of Food and Drug Safety (MFDS) in Korea. The AI analyzes endoscopy videos in real-time during the endoscopic examination to detect abnormal lesions in the stomach and colon. In particular, among the stomach and colon lineup, the stomach device is recognized as a Class 3 medical device that provides medical staff with suspected gastric cancer areas and gastric cancer probabilities, and was designated as the 37th innovative medical device by the MFDS in July for its technological innovation.

Starting from this business agreement, the two companies plan to promote sales and marketing activities of WAYMED Endo targeting major tertiary hospitals and medical institutions in Korea that perform stomach and colon endoscopy, utilizing Korea Pharma’s sales network and connections. They also stated that they will further collaborate on various AI-based solutions, including the panic disorder digital therapeutics (DTx) device currently being developed by Waycen.

Kim Kyung-nam, CEO of Waycen, said, “This business agreement with Korea Pharma, which has over 40 years of sales know-how in medical institutions, is not only about discovering new business opportunities but also the beginning of creating new trends in the endoscopy market,” adding, “We will work together to create a collaborative case recognized globally.” Park Eun-hee, CEO of Korea Pharma, also said, “Through cooperation with Waycen, we can provide clinically improved AI solutions to the increasing number of domestic gastrointestinal endoscopy patients every year,” and added, “We will continue to develop and introduce innovative medical technologies in various fields to contribute to public health.”